Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants having completed the VIPV-07 trial~2. Healthy assessed from medical history and physical examination~3. Parent(s)/guardian(s), according to the local legal requirements, have been properly informed about the trial and have signed the informed consent form~4. Parent(s)/guardian(s), according to the local legal requirements, have granted access to the infant's trial related medical records~5. Parent(s)/guardian(s), according to the local legal requirements, are likely to comply with trial procedures~Exclusion Criteria:~1. Previously vaccinated with OPV~2. Previously vaccinated with IPV outside the VIPV-07 trial~3. Known or suspected immunodeficiency (e.g. leukaemia or lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criterion~4. Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)~5. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)~6. Previous Yellow Fever vaccination~7. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~8. In treatment with systemic corticosteroids given p.o., i.v., i.m. ≤ 1 month prior to inclusion or during the trial. Subjects administered corticosteroid topically or by asthma inhalators are eligible for inclusion~9. Treatment with a product, which is likely to modify the immune response (e.g blood products and immunoglobulins) ≤ 3 months prior to inclusion or planned during the trial period~10. Participating in another interventional clinical trial~11. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- IPV-Al SSI (Type: EXPERIMENTAL): Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).